Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.39 |
| ▸ | SKP1 | P63208 | 2/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360123 | 0.83 | FAAH (0.38) | SIGMAR1MAPK1 | |
| SCHEMBL4369710 | 0.83 | CXCR2 (0.37) | — | |
| SCHEMBL4358423 | 0.81 | FAAH (0.40) | — | |
| SCHEMBL30254155 | 0.81 | ALDH1A1 (0.45) | MAPK1 | |
| SCHEMBL29155320 | 0.79 | SIGMAR1 (0.45) | SIGMAR1MAPK1 | |
| SCHEMBL4363955 | 0.71 | P2RY12 (0.40) | P2RY12CKS1BSKP1SKP2 | |
| SCHEMBL30020659 | 0.70 | NAMPT (0.46) | MKNK2 | |
| SCHEMBL25191894 | 0.70 | HPGD (0.45) | CKS1BSKP1SKP2MKNK2SIGMAR1 | |
| SCHEMBL7383181 | 0.70 | CYP3A4 (0.40) | SIGMAR1MAPK1 | |
| SCHEMBL3275117 | 0.69 | CKS1B (0.65) | CKS1BSKP1SKP2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | P2RY12 644/4885CKS1B 3175/4885SKP1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.